At the start of year, Generation Bio was revealed to the public, announcing that it had been developing gene therapies after a $25 million financing round led by Atlas.
After a little less than two months of this announcement, Generation Bio has been backed with a further $100 million from investors clearly keen on the idea of a gene therapy alternative to viral vectors.
